$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves Livsayis As First siRNA Myasthenia Treatment

The Food and Drug Administration approved Regeneron's Livsayis (cemdisiran) on November 18 for adults with anti-AChR antibody-positive generalized myasthenia gravis, the first siRNA therapy approved in the disease and the only approved treatment injected under the skin four times a year.

TML Health DeskNov 18, 8:16 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

An 1852 daguerreotype portrait of a man with ptosis, the drooping eyelid that is a hallmark sign of myasthenia gravis (archive). Photo: William Bell, Army Medical Museum, via Wikimedia Commons (public domain).
Summary

Livsayis reaches patients only through its restricted REMS program, and a European Union decision is expected in the second half of 2027.

Tap a passage. React to the part that matters.

For people with generalized myasthenia gravis, the failure sits where nerve meets muscle, and it shows up in chewing, swallowing and breathing. On November 18, the Food and Drug Administration approved Livsayis (cemdisiran), Regeneron's C5-directed small interfering RNA therapy, for adults who are anti-acetylcholine receptor antibody-positive, the predominant form of the disease.

Cemdisiran works upstream of the junction damage itself, because it degrades the messenger RNA that encodes the C5 protein, reducing circulating C5 levels and limiting the terminal complement activation that attacks the neuromuscular junction in this form of the disease. Regeneron said Livsayis is the first and only siRNA therapy approved in generalized myasthenia gravis and the only approved treatment for the disease administered subcutaneously four times a year, once every three months. The company developed the drug and will commercialize it under a worldwide licensing agreement with Alnylam.

The approval rests on the Phase 3 NIMBLE trial, a randomized, double-blind, placebo-controlled study Regeneron describes as the largest global interventional trial conducted in the disease. At 24 weeks, patients on Livsayis improved by 4.5 points on the Myasthenia Gravis-Activities of Daily Living scale against 2.2 points on placebo, a placebo-adjusted improvement of 2.3 points (p=0.0005), and the share of patients improving by at least 3 points on that scale was 76.6 percent on Livsayis against 44.1 percent on placebo. On the clinician-scored Quantitative Myasthenia Gravis scale, Livsayis patients improved by 4.2 points against 1.5 on placebo, and Regeneron reported clinically meaningful benefit as early as two weeks after treatment started.

"For people living with gMG, every day can be unpredictable, due to fluctuating muscle weakness and fatigue. They may also experience severe exacerbations that can be life-threatening," said Tuan Vu, M.D., a professor of neurology at the University of South Florida Morsani College of Medicine and a global principal investigator of the NIMBLE trial. "In the Phase 3 NIMBLE trial, Livsayis delivered rapid, deep disease control, maintained through the end of dosing intervals, and offers a four-times-a-year subcutaneous dosing schedule." Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America, said people with the disease can struggle with how they talk, see, breathe and move, and she called the approval a positive milestone for the community.

The label carries the safety terms that follow C5 reduction, starting with a boxed warning for serious meningococcal infections in the prescribing information. Livsayis is available only through a restricted program called the Livsayis REMS, under which patients must complete meningococcal vaccination at least two weeks before the first dose or receive antibiotics if treatment starts sooner, and the most common adverse reactions, each in at least 5 percent of treated patients and more frequent than placebo, were injection site reactions, viral infections and urinary tract infections. Generalized myasthenia gravis affects approximately 85,000 people in the United States, and a regulatory submission for Livsayis is under review in the European Union, with a decision expected in the second half of 2027.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.